Direct answer:FDA released the FY 2027 OTC Monograp Drug User Fee Programme (OMUFA) rate on 29 July 2026. The F.D.A. page lists F.Y. 2027 facility fees as: Monograph Drug Facility (MDF) $47,891 and Contractor Manufacturing Organization (CMO) $31,927; The OOMOR application fee is calculated on a separate basis based on Tier.The nature of the document, its current status and the enterprise proposal are set out below; Specific products should be judged in the official language.

What is this file, at what stage?

The regulatory document and its status referred to in this paper is based on the original FDA page listing. Rates vary by fiscal year; Not all OTC enterprises or sites automatically bear the same costs.

A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.

Which enterprises and products need attention?

Facilities for the production or commissioning of OTC specialized drugs, MDF/CMO operators and applicants for OOMOR costs.

It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.

Where is the change from what was previously requested?

The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.

FDA released the FY 2027 OTC Monograp Drug User Fee Programme (OMUFA) rate on 29 July 2026. The F.D.A. page lists F.Y. 2027 facility fees as: Monograph Drug Facility (MDF) $47,891 and Contractor Manufacturing Organization (CMO) $31,927; OOMOR application fees are calculated on a separate basis at Tier.

The scope of application first determines that:OMUFA facility fees applicable to FP-satisfactory&C Act defines OTC monochrap Drug facility and meets other conditions. FDA states that the cost of an OTC specialized pharmaceutical API is not applicable to facilities that do not meet the definition of the facility. The rates cannot be applied to all pharmaceutical plants.

FDA states that the facility fee is paid in two instalments: the first 50 per cent, normally due on 1 October 2026; The second phase is 50 per cent remaining and expires on 1 February 2027. If the relevant appropriations law has not yet entered into force, the statutory date may be extended to the first working day after the entry into force of the appropriation, as per the FDA page. Based on the FDA official bulletin and payment system.

  1. Whether the facility produces OTC-specific drugs and whether it is a statutory charger.
  2. The facility belongs to MDF or CMO and checks the FDA definition of CMO.
  3. Whether information on the activities of the facility has been updated to the FDA, in particular in cases where activities have been discontinued.
  4. Distinguishing the facility fee from the OOMOR request fee and identifying the corresponding contributors.
  5. Check the invoice, payment period, official account number and payment status.

Key dates and transitional arrangements

The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.

  • 29 July 2026: Date of issuance of the document (as expressed in the original language of the adjacent official).
  • 1 October 2026: Dates listed in the document (as expressed in the original language of the adjacent official).
  • 1 February 2027: Entry into force/application of node (as expressed in the original language of the adjacent official).

The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.

How can Chinese companies prepare?

  1. Check the statutory definition of facilities, the FY 2027 rate, the date of the instalment payment, the conditions of durability triggered by the appropriation method and the qualification of small businesses.
  2. Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
  3. If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.

For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.

Exceptions, pending confirmations and common misreading

  • Rates vary by fiscal year; Not all OTC enterprises or sites automatically bear the same costs.
  • When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
  • Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.

Official information and reconciliation records

(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.

Next

Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.